Archives

The controversy over prostate cancer treatment Provenge came to a head in the Seattle area Friday, as roughly 15 people rallied in front of Westlake Center and outside the FDA offices in Bothell, urging the FDA to approve the therapy.
[Read More]

Kevin DeGeeter, an analyst at Oppenheimer & Co., put out a report today saying that Recothrom, ZymoGenetics’ treatment to stop bleeding during surgery, had $92,589 in April sales, substantially below his estimate of $750,000 for the month. He cited IMS, the market research firm.
[Read More]

As I mentioned in my story on the OncoGenex-Sonus deal today (read it here), Vancouver, B.C.-based OncoGenex already had operations in Seattle prior to the announcement of its merger with Bothell’s Sonus Pharmaceuticals.
[Read More]

Seven months after announcing it was looking for strategic alternatives after a failed clinical trial, Bothell’s Sonus Pharmaceuticals said it would merge with Vancouver, B.C.-based OncoGenex Technologies.
[Read More]